Long-term benefit of thrombolytic therapy in patients with pulmonary embolism

Vascular Medicine

Volumn 5, Issue 2, 2000, Pages 91-95

  Sharma, G V R K ^a,d   Folland, Edward D ^b   McIntyre, Kevin M ^a   Sasahara, Arthur A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Long term hemodynamic and clinical benefit; Pulmonary embolism; Thrombolytic therapy

Indexed keywords

HEPARIN; STREPTOKINASE; UROKINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FIBRINOLYTIC THERAPY; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0033929837     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x0000500205     Document Type: Article

References (19)

1. The Urokinase Pulmonary Embolism Trial: A national cooperative study. Circulation 1973; 47: II-1-108.
2. Urokinase-Streptokinase Pulmonary Embolism Trial. Phase II results: a cooperative study. JAMA 1974; 229: 1606-13.
3. Goldhaber SZ, Vaughan DE, Markis JE et al. Acute pulmonary embolism treated with tissue plasminogen-activator. Lancet 1986; ii: 886-89.
4. Verstraete M, Miller GAH, Bounameaux H et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-60.
5. Goldhaber SZ, Kessler CM, Heit J et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; ii: 293-98.
6. Dalla-Volta S, Palla A, Santolicandro AM et al. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italial Multicenter Study 2. J Am Coll Cardiol 1992; 20: 520-26.
7. Goldhaber SZ, Kessler CM, Heit JA et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
8. Meyer G, Sors H, Charbonnier B et al, on behalf of the European Cooperative Study Group for Pulmonary Embolism. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double blind trial. J Am Coll Cardiol 1992; 19: 239-45.
9. Come PC, Kine D, Parker JA et al and participating investigators. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987; 10: 971-78.
10. Goldhaber SZ, Haire WD, Feldstein ML et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-11.
11. Sharma GVRK, Burleson VA, Sashara AA. Effect of thrombolytic therapy on pulmonary capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842-45.
12. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17: 259-70.
13. Paraskos JA, Adelstein SJ, Smith RE et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973; 289: 55-58.
14. Hall RJC, Sutton GC, Kerr IH. Longterm prognosis of treated acute massive pulmonary embolism. Br Heart J 1977; 69: 1128-34.
15. Riedel M, Prerovsky I, Stanek V et al. Chronic thromboembolic disease: longterm follow-up. Prog Respir Res 1980; 13: 134-40.
16. DeSoyza NDB, Murphy ML. Persistent post-embolic pulmonary hypertension. Chest 1972; 62: 665-68.
17. Schwartz F, Stehr H, Zimmermann R et al. Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation 1985; 71: 117-23.
18. Sharma GVRK, O'Connell DJ, Belko JS et al. Thrombolytic therapy for deep vein thrombosis. In: Paoletti R, Sherry S (eds). Thrombosis and urokinase. New York: Academic Press, 1977: 181-91.
19. Turpie AG, Levine MN, Hirsh J et al. Tissue plasminogen activator (γ-tPA) vs heparin in deep vein thrombosis: results of a randomized trial. Chest 1990; 97 (4 suppl): 172S-75S.